Overall survival and quality of life superiority in modern phase III oncology trials. Benefit of adding Cureety remote patient monitoring (RPM) to usual care during injectable anticancer treatment: ...

Researchers from SWOG Cancer Research Network, a cancer clinical trials group funded by the National Cancer Institute (NCI), part of the National Institutes of Health (NIH), will share results of ...

CHICAGO — June 5, 2017 — For an investment of $125 for each year of life gained since the 1950s, the National Cancer Institute-funded SWOG clinical trials program has added 3.34 million years of life ...

SWOG Clinical Trials Partnerships (SWOG CTP) has signed a collaborative research agreement with Novartis Pharmaceuticals Corporation to form a strategic alliance via our Preferred Partnership Program ...

Natera (NTRA) announced the publication of findings from the randomized, phase III CALGB/SWOG 80702 study in JAMA Oncology. This publication ...

IRVINE, Calif., Oct. 06, 2022 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company with the mission to improve patient outcomes by providing personalized insights ...

Readout of ~1K patients at ASCO GI 2025 demonstrates that Signatera™ positive patients treated with both chemotherapy and celecoxib had a 40% improvement in overall survival versus chemotherapy alone ...

The SWOG S1011 randomized phase 3 trial found no significant improvement in disease-free or overall survival but a higher rate of grade 3-4 adverse events and an increased risk of death in the 90 days ...

Dr. Michael LeBlanc of Fred Hutchinson Cancer Research Center has been named the new group statistician of SWOG, heading its Statistical Center. Formerly known as the Southwest Oncology Group, SWOG is ...